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Objectives: To assess the performance of the agar disc diffusion method for the detection of carbapenemase-
producing Enterobacteriaceae (CPE) referred to the national reference laboratories (NRLs) in Belgium and France.
Methods: All Enterobacteriaceae isolates referred to the NRLs for the confirmation of CPE in 2012 were included.
The inhibition zone diameters of meropenem, piperacillin/tazobactam and temocillin using CLSI disc diffusion
methodology were recorded. Phenotypic and molecular detection of carbapenemases was performed on all
isolates.
Results: A total of 1354 Enterobacteriaceae isolates, including 435 (32.1%) confirmed CPE isolates [OXA-48
(n¼323), KPC (n¼60), VIM (n¼32) and NDM (n¼20)] and 919 carbapenemase-negative isolates, were tested.
Using recommended interpretative criteria, non-susceptibility to meropenem had poor sensitivity (52.0% by
CLSI susceptibility breakpoint and 80.0% by EUCAST screening breakpoints), while non-susceptibility to piperacil-
lin/tazobactam(according toCLSIbreakpoint)or to temocillin (accordingtoFuchs,Barry, Thornsberryet al. Eur J Clin
Microbiol 1985; 4: 30–3) was highly sensitive (99.8% and 98.2%, respectively) but poorly specific (29.4% and
42.9%, respectively) for the detection of CPE. Temocillin diameters ,12 mm alone had high specificity (90.0%)
and the combination of temocillin diameters≥12 mmwith piperacillin/tazobactamdiameters≥16 mmobserved
in 40% of all referred isolates displayed excellent negative predictive value (99.2%).
Conclusions: In geographical areaswith a high prevalence of OXA-48 producers, recommendedmeropenem sus-
ceptibility or screening breakpoints failed to detect CPE in a large proportion of isolates. The combination ofmodi-
fiedzonediametercut-offs forpiperacillin/tazobactam(≥16 mm)andtemocillin (≥12 mm)canbeusedto ruleout
the presence of carbapenemase and avoid unnecessary additional testing for confirmation of CPE.
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Introduction
Carbapenemase-producing Enterobacteriaceae (CPE) isolates
have been increasingly reported worldwide.1 Klebsiella pneumo-
niae is by far the most frequently encountered CPE species and
OXA-48 the most frequent carbapenemase in Belgium and in
France.2,3 Rapid detection of CPE is essential for the control of
their dissemination. Ertapenem non-susceptibility has been pro-
posed as the most sensitive marker for the detection of CPE
strains, but has shown poor positive predictive value, particularly
in geographic areas with a low-prevalence setting.4 Furthermore,
phenotypic methods for the confirmation of carbapenemase
production based on the use of inhibitor-supplemented
antimicrobial discs allow differentiation between Ambler class
A and B carbapenemase producers, but fail to confirm Ambler
class D OXA-48-producing CPE. In this study, we evaluated in
two different national reference laboratories (NRLs) the ability
to detect CPE in carbapenem-non-susceptible Enterobacteria-
ceae (CNSE) by using the disc diffusion method, with a particular
focus on OXA-48-producing Enterobacteriaceae isolates.
# The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
For Permissions, please e-mail: journals.permissions@oup.com
J Antimicrob Chemother 2014; 69: 445–450
doi:10.1093/jac/dkt367 Advance Access publication 20 September 2013
445
Methods
All Enterobacteriaceae isolates referredby local laboratories to theNRLs for
non-susceptibility to at least one carbapenem (ertapenem, imipenem,
meropenem) according to local routine practice were included for the
period from January to December 2012 in Belgiumand fromMarch to Sep-
tember 2012 in France. In France, themajority of the laboratories adhered
to the recommendations issued by the Comite´ de l’Antibiogramme de la
Socie´te´ Franc¸aise de Microbiologie (CA-SFM),5 while in Belgium the CLSI6
and EUCAST7 guidelineswere variably used. All isolateswere tested for imi-
penem hydrolysis by the Carba NP assay as previously reported8 and those
with a positive test result underwentmultiplex PCR targeting blaVIM, blaIMP,
blaNDM, blaKPC and blaOXA-48 for the detection of carbapenemase-encoding
genes.9 Inhibition zone diameters of meropenem 10 mg, piperacillin/
tazobactam 100/10 mg and temocillin 30 mg paper discs (Bio-Rad) tested
according to CLSI disc diffusion methodology10 were measured for all
isolates. The recommended susceptibility zone diameter breakpoints
chosen in this study were meropenem ≥23 mm, piperacillin/tazobactam
≥21 mm (according to CLSI guidelines)10 and temocillin ≥19 mm (based
on disc diffusion interpretative criteria proposed by Fuchs et al.11). To
ensure the relationship between disc diffusion inhibition zone diameters
andmicrodilutionMICs, 76 randomly selected isolates underwent in paral-
lel MIC determination for meropenem and piperacillin/tazobactam using
brothmicrodilution panels (Sensititrew, Thermo Fisher Scientific, Cleveland,
USA). TheMICvalueof temocillinwasdeterminedby theEtestmethod (bio-
Me´rieux, Marcy-l’E´toile, France).
Results and discussion
In 2012, 635 Enterobacteriaceae isolates referred to the Belgian
NRL and 719 referred to the French NRL were analysed. Species
and carbapenemase type distribution of the isolates are detailed
for each NRL in Table 1. Overall, from a total of 1354 Enterobacter-
iaceae isolates screened, 435 (32.1%)were confirmedas carbape-
nemase producers [OXA-48 (n¼323), KPC (n¼60), VIM (n¼32)
and NDM (n¼20)]. While the proportions of each species referred
to theNRLswere slightlydifferent (ahighernumberofEnterobacter
cloacae isolates was analysed in France), the proportions of each
carbapenemase type and species among confirmed CPE isolates
were similar. In Enterobacter spp. decreased susceptibility to erta-
penem is common due to extended-spectrum b-lactamase or
cephalosporinase production in conjunction with permeability
defects.12 Therefore, the higher number of E. cloacae isolates re-
ferred in Francemaybeattributed to thesystematic testingof erta-
penem by laboratories and the higher screening breakpoint
recommended by the CA-SFM (,28 mm) in comparison with the
CLSI and EUCAST guidelines used in Belgium.
The distributions of meropenem, piperacillin/tazobactam
and temocillin inhibition zone diameters as well as the
carbapenemase-encodinggenesare shown inFigures1–3, respect-
ively. Scattergrams for meropenem, piperacillin/tazobactam and
Table 1. Species and carbapenemase enzyme distribution of Enterobacteriaceae isolates referred to the NRLs in 2012 for confirmation of CPE
(n¼1354)
Country of NRL Species Total
Carbapenemase
OXA-48 KPC VIM NDM negative
Belgium Klebsiella pneumoniae 273 138 35 3 1 96
Enterobacter cloacae 97 13 8 2 74
Escherichia coli 69 21 1 2 2 43
Enterobacter aerogenes 82 1 81
Klebsiella oxytoca 37 8 2 3 24
Citrobacter freundii 20 7 3 10
miscellaneousa 57 2 2 1 52
total 635 190 38 21 6 380
France K. pneumoniae 266 94 21 4 6 141
E. cloacae 237 11 1 2 223
E. coli 90 23 4 63
E. aerogenes 46 1 45
K. oxytoca 5 5
C. freundii 29 1 1 5 22
miscellaneousb 46 3 1 2 40
total 719 133 22 11 14 539
Total 1354 323 60 32 20 919
aProteus mirabilis (n¼6), Serratia marcescens (n¼13), Hafnia alvei (n¼3), Morganella morganii (n¼2), Enterobacter spp. (n¼28), Citrobacter spp. (n¼1),
Raoultella spp. (n¼1), Providencia spp. (n¼2) and Salmonella spp. (n¼1).
bP. mirabilis (n¼12), S. marcescens (n¼4), H. alvei (n¼7), M. morganii (n¼6), Enterobacter spp. (n¼8), Citrobacter spp. (n¼5), Raoultella spp. (n¼3) and
Salmonella spp. (n¼1).
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temocillin arepresented inTables S1, S2andS3 (availableas Supple-
mentary data at JACOnline). A significant correlation between zone
diameters and MICs was found for the three antimicrobials
evaluated (Pearson’s correlation coefficient r was 20.859,20.746
and20.845 for meropenem, piperacillin/tazobactam and temocil-
lin, respectively; P,0.001).
Sensitivity, specificity and positive and negative predictive
values for the detection of carbapenemase production according
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Figure 1. Distribution of meropenem 10 mg disc inhibition zone and of carbapenemases for Enterobacteriaceae isolates referred to the NRLs in 2012
(n¼1354). (a) 2013 CLSI meropenem disc diffusion susceptibility zone diameter breakpoint (≥23 mm). (b) 2013 EUCAST meropenem susceptibility
zone diameter breakpoint (≥22 mm). (c) 2013 EUCASTmeropenem disc diffusion screening cut-off for the detection of CPE (,25 mm).
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Figure 2. Distribution of piperacillin/tazobactam100/10 mg disc inhibition zone and of carbapenemase enzymes for Enterobacteriaceae isolates referred
to the NRLs in 2012 (n¼1354). (a) 2013 CLSI piperacillin/tazobactam disc diffusion susceptibility zone diameter breakpoint (≥21 mm). (b) Piperacillin/
tazobactammodified cut-off proposed in this study (,16 mm).
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to the antimicrobial agents tested and zone diameter cut-offs
selected are detailed in Table 2. Using the recommended 23 mm
diameter breakpoint for meropenem, 209 (48.0%) of the CPE
tested were characterized as susceptible [OXA-48 (n¼198), VIM
(n¼9), NDM (n¼1) and KPC (n¼1)]. With the exception of eight
carbapenemase producers [KPC (n¼6) and NDM (n¼2)], all CPE
isolates were resistant to temocillin, including all OXA-48 isolates,
which notably exhibited decreased susceptibility to piperacillin/
tazobactam in all but one isolate. Recently, a subcommittee of
EUCAST proposed tentative guidelines for the detection of
resistance mechanisms and specific resistances of clinical and/or
epidemiological importance.13 A screeningbreakpoint formerope-
nem ,25 mm was suggested. Applying this screening cut-off
would have resulted in an improved but still insufficient sensitivity
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Figure3. Distributionof temocillin 30 mgdisc inhibition zoneandof carbapenemaseenzymes for Enterobacteriaceae isolates referred to theNRLs in 2012
(n¼1354). (a) Temocillin disc diffusion susceptibility zone diameter breakpoint according to Fuchs et al.11 (≥19 mm). (b) Temocillin modified cut-off
proposed in this study (,12 mm).
Table 2. Carbapenemase distribution according to different inhibition diameters cut-offs and their performance for the detection of CPE among
isolates referred to the NRLs in France and in Belgium in 2012 (n¼1354)
Zone diameter cut-offs
(mm)
Total,
1354
Number of isolates per carbapenemase enzyme Performance of the detection of CPE
OXA-48,
323
KPC,
60
VIM,
32
NDM,
20
negative,
919
sensitivity
(%)
specificity
(%)
PPV
(%)
NPV
(%)
Susceptibility
breakpointsa
MEM,23 452 125 59 23 19 226 52.0 75.4 49.9 76.8
TZP,21 1083 322 60 32 20 649 99.8 29.4 40.0 99.6
TMO,19 952 323 54 32 18 525 98.2 42.9 44.8 98.0
Modified cut-offs MEM,29 929 322 60 32 20 495 99.8 46.1 46.6 99.8
TZP,16 790 319 59 30 19 363 98.2 60.5 54.0 98.6
TMO,12 457 317 8 28 12 92 83.9 90.0 79.9 92.2
Combination of
cut-offs
TZP,16 and TMO,12 426 315 8 26 12 65 83.0 92.9b 84.7
TZP ≥16 and TMO≥12 533 2 1 1 529 99.2
MEM, meropenem 10 mg disc; TZP, piperacillin/tazobactam 100/10 mg disc; TMO, temocillin 30 mg disc; PPV, positive predictive value; NPV, negative
predictive value. The results shown in bold are discussed further in the text.
aAccording to 2013 CLSI guidelines (for meropenem and piperacillin/tazobactam) and to Fuchs et al.11 (for temocillin).
bThe specificity of combined cut-offs was calculated for carbapenemase-negative isolates when at least one of the two criteria was not fulfilled.
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of 80% for the detection of CPE, mainly missing OXA-48 (80/323)
and VIM-positive (6/32) isolates. Day et al.14 reported excellent
sensitivities (99%) of different carbapenem (ertapenem, imipen-
em, meropenem and faropenem) discs and the superior specifi-
city (94%) of faropenem for the screening of CPE isolates.
However, this study was conducted in a setting with a different
distribution of carbapenemase types, mostly including a large
number of NDM producers and a small number of OXA-48-positive
strains.
When modified cut-offs were applied (meropenem ,29 mm,
piperacillin/tazobactam,16 mmor temocillin,12 mm), sensitiv-
ity for meropenem was increased to 99.8% while sensitivity for
piperacillin/tazobactamremainedhighat98.2%.However, specifi-
cities using these cut-offs were low for both meropenem (46.0%)
and piperacillin/tazobactam (60.5%). With regard to temocillin,
98.1% (317/323) of the OXA-48-producing Enterobacteriaceae
isolates displayed disc inhibition zones of ,12 mm compared
withonly10.0%(92/919)of thecarbapenemase-negative isolates.
Amore variable distribution of temocillin inhibition zone diameters
was found in KPC- and NDM-producing isolates (range 10–28 and
6–24 mm, respectively), although the large majority of
KPC-producing isolates (52/60) had inhibition zone diameters of
≥12 mm.
These results support previous data and confirm that high-level
resistance to temocillin is a highlysensitive and specific phenotypic
surrogate marker of OXA-48 production in strains with decreased
susceptibility to a carbapenem, although in itself it could not
differentiate OXA-48 from VIM-type carbapenemases.15–17
When comparing the results obtained for K. pneumoniae with
those for other Enterobacteriaceae species, no significant differ-
ence in sensitivity of CPE detection was found for either merope-
nem or piperacillin/tazobactam discs regardless of whether the
recommended or the modified cut-offs were applied. Using
the modified cut-off of temocillin ,12 mm, the specificity and
the positive predictive value for the detection of carbapenemase
production were higher in K. pneumoniae (92.0% and 92.9%,
respectively) than in other species (89.3% and 61.8%) in which
non-carbapenemase mediated resistance to temocillin is more
frequently encountered. When applied in geographical areas
where OXA-48 represents the predominant carbapenemase, the
combination of a piperacillin/tazobactam inhibition zone
,16 mm with a temocillin zone ,12 mm appeared to be highly
predictive of carbapenemase production, especially in K. pneumo-
niae (positive predictive value of 94.6%), while the association of a
piperacillin/tazobactam inhibition zone≥16 mmwith a temocillin
zone ≥12 mm ruled out the presence of a carbapenemase in
40% (529/1354) of all isolates tested (negative predictive value
of 99.2%). Since according to the design of our protocol only
strains with a positive Carba NP test were selected for molecular
identification of carbapenemases, we retrospectively analysed a
subset of isolates displaying high-level resistance to temocillin
and to piperacillin/tazobactam, but with a negative Carba NP test
result. Overall, none of the 26 available isolates tested (out of 65
isolates) yielded a positive multiplex PCR result, hence excluding
the presence of carbapenemases (most notably OXA-48) that
could have been missed by the Carba NP test-based algorithm.
In conclusion, our study showed thatmeropenemCLSI suscep-
tibility breakpoints by the disc diffusion method or cut-off dia-
meters recently proposed by EUCAST10,13,18 fail to detect a
substantial proportion of CPE isolates, predominantly OXA-48-
producers. This observation is of concern since a large number of
microbiology laboratories (50%–60% in Belgium) still rely on the
disc diffusion method as the principal method for routine suscep-
tibility testing. Piperacillin/tazobactam and temocillin resistances
are highly sensitive surrogate markers for CPE and our study sug-
gests that concomitant susceptibility of CNSE isolates to these
two antimicrobials could reliably rule out the presence of a carba-
penemase, thuspreventingunnecessaryadditional testing. Finally,
in areas where OXA-48 producers are predominant, temocillin
testing using a modified zone diameter cut-off of ,12 mm and/
or an MIC .128 mg/L16 could be an easy and useful tool for dis-
criminating Ambler class D carbapenemase producers from
extended-spectrum b-lactamases and/or AmpC-producing iso-
lates among carbapenem-non-susceptible Enterobacteriaceae
isolates that yield a negative result by the inhibitor-based combin-
ation disc test.19 Our findings should, however, be evaluated in
areas with different epidemiological backgrounds of carbapene-
mase enzymes.
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